Saved in:
| Title: | Cell Therapy cGMP Facilities and Manufacturing / |
|---|---|
| From: |
edited by Adrian P. Gee.
|
| Person: |
Gee, Adrian P.
editor. |
| Corporate Author: | |
| Other Authors: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2022.
|
| Edition: | 2nd ed. 2022. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-030-75537-9 |
| Summary: | This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. . |
| Physical Description: | 1 Online-Ressource (X, 692 p. 107 illus., 75 illus. in color.) |
| ISBN: | 9783030755379 |
Staff View
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | ZDB-2-SBL-978-3-030-75537-9 | ||
| 003 | DE-He213 | ||
| 005 | 20240912174910.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 211110s2022 sz | o |||| 0|eng d | ||
| 020 | |a 9783030755379 |9 978-3-030-75537-9 | ||
| 024 | 7 | |a 10.1007/978-3-030-75537-9 |2 doi | |
| 050 | 4 | |a QH573-671 | |
| 072 | 7 | |a PSF |2 bicssc | |
| 072 | 7 | |a SCI017000 |2 bisacsh | |
| 072 | 7 | |a PSF |2 thema | |
| 082 | 7 | |a 571.6 |2 23 | |
| 245 | 1 | 0 | |a Cell Therapy |h [electronic resource] : |b cGMP Facilities and Manufacturing / |c edited by Adrian P. Gee. |
| 250 | |a 2nd ed. 2022. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2022. | |
| 300 | |a 1 Online-Ressource (X, 692 p. 107 illus., 75 illus. in color.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software - Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards MeasurementAssurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States. | |
| 520 | |a This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. . | ||
| 650 | 0 | |a Cytology. | |
| 650 | 0 | |a Pharmacovigilance. | |
| 650 | 0 | |a Facility management. | |
| 650 | 1 | 4 | |a Cell Biology. |
| 650 | 2 | 4 | |a Drug Safety and Pharmacovigilance. |
| 650 | 2 | 4 | |a Facility Management. |
| 700 | 1 | |a Gee, Adrian P. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783030755355 |
| 776 | 0 | 8 | |i Printed edition: |z 9783030755362 |
| 966 | 4 | 0 | |l DE-355 |p ZDB-2-SBL |q UBG_PDA_SBL |u https://doi.org/10.1007/978-3-030-75537-9 |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 912 | |a ZDB-2-SBL | ||
| 049 | |a DE-355 | ||
Record in the Search Index
| DE-BY-UBR_katkey | ZDB-2-SBL-978-3-030-75537-9 |
|---|---|
| _version_ | 1835726563284353024 |
| adam_text | |
| any_adam_object | |
| author2 | Gee, Adrian P. |
| author2_role | edt |
| author2_variant | a p g ap apg |
| author_corporate | SpringerLink (Online service) |
| author_corporate_role | |
| author_facet | Gee, Adrian P. SpringerLink (Online service) |
| building | Verbundindex |
| bvnumber | localUBR |
| callnumber-first | Q - Science |
| callnumber-label | QH573-671 |
| callnumber-raw | QH573-671 |
| callnumber-search | QH573-671 |
| callnumber-sort | QH 3573 3671 |
| callnumber-subject | QH - Natural History and Biology |
| collection | ZDB-2-SBL ZDB-2-SXB |
| contents | Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software - Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards MeasurementAssurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States. |
| dewey-full | 571.6 |
| dewey-hundreds | 500 - Natural sciences and mathematics |
| dewey-ones | 571 - Physiology & related subjects |
| dewey-raw | 571.6 |
| dewey-search | 571.6 |
| dewey-sort | 3571.6 |
| dewey-tens | 570 - Biology |
| discipline | Biologie |
| edition | 2nd ed. 2022. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05532nam a22004815i 4500</leader><controlfield tag="001">ZDB-2-SBL-978-3-030-75537-9</controlfield><controlfield tag="003">DE-He213</controlfield><controlfield tag="005">20240912174910.0</controlfield><controlfield tag="007">cr nn 008mamaa</controlfield><controlfield tag="008">211110s2022 sz | o |||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783030755379</subfield><subfield code="9">978-3-030-75537-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-030-75537-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QH573-671</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PSF</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">SCI017000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PSF</subfield><subfield code="2">thema</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">571.6</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cell Therapy</subfield><subfield code="h">[electronic resource] :</subfield><subfield code="b">cGMP Facilities and Manufacturing /</subfield><subfield code="c">edited by Adrian P. Gee.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2nd ed. 2022.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer International Publishing :</subfield><subfield code="b">Imprint: Springer,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 692 p. 107 illus., 75 illus. in color.) </subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software - Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards MeasurementAssurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. .</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cytology.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacovigilance.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Facility management.</subfield></datafield><datafield tag="650" ind1="1" ind2="4"><subfield code="a">Cell Biology.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Drug Safety and Pharmacovigilance.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Facility Management.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gee, Adrian P.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">SpringerLink (Online service)</subfield></datafield><datafield tag="773" ind1="0" ind2=" "><subfield code="t">Springer Nature eBook</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783030755355</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783030755362</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">UBG_PDA_SBL</subfield><subfield code="u">https://doi.org/10.1007/978-3-030-75537-9</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SXB</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (SpringerNature-11642)</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (R0) (SpringerNature-43708)</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield></record></collection> |
| id | ZDB-2-SBL-978-3-030-75537-9 |
| illustrated | Not Illustrated |
| indexdate | 2025-06-23T13:27:55Z |
| institution | BVB |
| isbn | 9783030755379 |
| language | English |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 692 p. 107 illus., 75 illus. in color.) |
| psigel | ZDB-2-SBL UBG_PDA_SBL ZDB-2-SBL ZDB-2-SXB |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Springer International Publishing : Imprint: Springer, |
| record_format | marc |
| spelling | Cell Therapy [electronic resource] : cGMP Facilities and Manufacturing / edited by Adrian P. Gee. 2nd ed. 2022. Cham : Springer International Publishing : Imprint: Springer, 2022. 1 Online-Ressource (X, 692 p. 107 illus., 75 illus. in color.) text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software - Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards MeasurementAssurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States. This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. . Cytology. Pharmacovigilance. Facility management. Cell Biology. Drug Safety and Pharmacovigilance. Facility Management. Gee, Adrian P. editor. edt http://id.loc.gov/vocabulary/relators/edt SpringerLink (Online service) Springer Nature eBook Printed edition: 9783030755355 Printed edition: 9783030755362 |
| spellingShingle | Cell Therapy cGMP Facilities and Manufacturing / Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software - Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards MeasurementAssurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States. Cytology. Pharmacovigilance. Facility management. Cell Biology. Drug Safety and Pharmacovigilance. Facility Management. |
| title | Cell Therapy cGMP Facilities and Manufacturing / |
| title_auth | Cell Therapy cGMP Facilities and Manufacturing / |
| title_exact_search | Cell Therapy cGMP Facilities and Manufacturing / |
| title_full | Cell Therapy [electronic resource] : cGMP Facilities and Manufacturing / edited by Adrian P. Gee. |
| title_fullStr | Cell Therapy [electronic resource] : cGMP Facilities and Manufacturing / edited by Adrian P. Gee. |
| title_full_unstemmed | Cell Therapy [electronic resource] : cGMP Facilities and Manufacturing / edited by Adrian P. Gee. |
| title_short | Cell Therapy |
| title_sort | cell therapy cgmp facilities and manufacturing |
| title_sub | cGMP Facilities and Manufacturing / |
| topic | Cytology. Pharmacovigilance. Facility management. Cell Biology. Drug Safety and Pharmacovigilance. Facility Management. |
| topic_facet | Cytology. Pharmacovigilance. Facility management. Cell Biology. Drug Safety and Pharmacovigilance. Facility Management. |
| work_keys_str_mv | AT geeadrianp celltherapycgmpfacilitiesandmanufacturing AT springerlinkonlineservice celltherapycgmpfacilitiesandmanufacturing |